secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001140361-25-041269
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q2 net loss $113.5M; brepocitinib Phase 3 DM trial succeeds on all endpoints
--------------------------------------------------------------------------------

- Brepocitinib 30 mg met primary and all nine key secondary endpoints in Phase 3 VALOR DM study; NDA filing planned H1 2026.
- Net loss attributable to Roivant $113.5M ($0.17/sh) vs $230.2M ($0.31) a year ago; revenue $1.6M.
- Cash and marketable securities $4.4B as of Sept 30, 2025; R&D spend $164.6M (up 15% YoY).
- Immunovant batoclimab TED: first Phase 3 readout by end-2025, but both studies to release concurrently in H1 2026 due to competitive dynamics.
- Favorable Markman ruling in Pfizer/BioNTech LNP litigation; Moderna jury trial scheduled March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125041269/0001140361-25-041269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125041269/ef20058314_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer